GIVD Classification 2021 Update - Input from Companies Welcomed
Your Chance to Modify the BIVDA Market Audit (Coronavirus included).
Does your company participate in the BIVDA Market Audit? 95% of the industry turnover is represented in this comprehensive, twice-yearly audit, and participants benefit by receiving detailed analysis of market sizes and trends down to the level of individual test types and technologies.
Every year the MedTech Europe Market Research Committee look at the Global IVD (GIVD) Classification which is used for the BIVDA Market Audit as well as all the other national surveys that make up the Global Diagnostic Manufacturer's Survey (GDMS) of the world IVD market. Inputs from participating companies are considered, and, if agreed, are incorporated into the classification. So, if your company has a test for a particular analyte and would like to see data on the market revenues, you can submit a request via John Bagshaw ( firstname.lastname@example.org ) to have it included.
Recent additions other than Coronavirus have included changes to the categorisations of rapid test strips, particularly for urinanalysis, and for automated urine screening systems. Over recent years particular analytes such as Calprotectin, Procalcitonin, new cancer markers and molecular infectious disease assays and new rapid tests have been specified and incorporated.
Take a look at the GIVD here and see if you would like any new tests to be included, or existing tests separated from groups and shown individually. Or just send John a query and he will check for you.
The deadline for changes to be proposed is 30th September, so there is plenty of time, but the sooner done the clearer we can be on the reasons and benefits for doing it.
AND - don't forget, if you participate in the BIVDA Market Audit we need your data for the first half of 2020 NOW! Please ensure it has been submitted so we can consolidate and get you the report back as soon as possible.